Questions related to ACT
Carpomyia vesuviana Costa is monophagous, destructive pests, and endogenous species infesting on Zizyphus spp.
I have tried many primers with gradient PCR for their molecular identification but they and not working properly.
X-F: 5′-ACG ATG ATG CGA TTG GTG AC-3 ′
X-R: 5′-TAT TGG TCG CGG AAC AAA CC-3 ′
COI CLepFolF 5'---ATT CAA CCA ATC ATAAAG ATA TTG G
CLepFolR 5'--TAA ACT TCT GGA TGT CCA AAA AAT CA
LCO1490 and HCO2198
Now I would like to model a simple system that a benzene on a Au(111) surface.
However, as I know the reaxFF parameter from the paper:
Jarvi, T.T., van Duin, A.C.T., Nordlund, K. and Goddard, W.A. (2011) Development of interatomic ReaxFF potentials for Au-S-C-H systems. Journal of Physical Chemistry C 115, 10315-10322
The force field was parameterized for sp3 carbon system. Does anyone have any experience to model the case for sp2?
I have created an extension for Ansys workbench from a recorded script which has been recorded by Ansys ACT app builder from what I did manually in Workbench and CFD-Post. Since Ansys ACT app builder does not support CFD-Post as an stand alone product, I chose Ansys workbench as the product which I want to create the extension for it.
The extension works well and does what I did in Workbench and CFD-Post automatically but the problem is that I want to give some general inputs to it. Currently it works by the result file (.CDAT) and values which I gave in CFD-Post but I want to make the input result file (.CDAT) and some of the other parameters, general inputs for the extension.
There is a video below which shows how easy is to do this for an Ansys ACT extension which is based on a recorded script from Ansys AIM.
I want to do the same for my extension but it seems giving inputs and parameters to an Ansys ACT extension for Ansys Workbench is different and it can not be done in the same way.
I would be happy if you share your ideas with me about this problem.
Thank you in advance.
Absorption coefficient value is required in moving heat source ACT in ansys. I want to know where can I find this value or how can I calculate it experimentally?
I had an alarming e-mail from Clinicaltrial.gov, requesting the adding of the results in templates, just like a paper for publication, not a summary.
should I put them? and if so, should I talk to publisher first?
It was in 2016, and the completion date was before January 2017.
Part of e-mail:
FDA and NIH may take action against responsible parties if they do not submit required results information. Failure to submit required results information is a prohibited act under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 331(jj)(2), for which FDA could pursue civil monetary penalties under 21 U.S.C. 333(f)(3) against the ACT’s responsible party.
I am looking for recommended valid measures/questionnaires to measure a change in psychological flexibility. To be delivered pre and post intervention. Can either measure psychological flexibility as a whole, or measure the subcategories of the ACT hexaflex (or both). It is intended to be delivered to a population diagnosed with non-epileptic attacks.
All recommendations are warmly welcomed,
I have a model. I made the definition of model material. After the mesh, I selected a group of elements and I would like to assign to these elements other material properties different from that of model. To be able to do this, you must create an extension with ANSYS ACT. How to create this extension please?
How to create extension of Material Assignment to element Named Selection using ansys workbench ?
I really need the extension for the Additive manufacturing for Ansys 19 , I can't get it from the store as I have an academic licence and can't create an account.
What is the right logarithm to use to calculate how many people with serious mental illness need other services other than ACT or FACT?
Hello all out there _ have found calculations regarding ACT ans FACT but nothing beyond that re need and appropriateness for other services _ happy to have input from others _ Deb
I am trying to create node coupling between two opposite faces, edges and vertices.
My geometry is cubic (or rectangular cuboid), with complex structure enclosed by smooth faces of the cube.
I understand that I need to start the mesh from the faces, couple opposite nodes, and then create volume mesh with 3D tetrahedron elements to mesh the rest of the enclosed geometry.
I tried to work through the Ansys ACT developer guide, and I do manage to write some customized files. However, I can't manage to find a way to control the mesh generation through the ACT scripting.
What will be the best way to generate this type of meshing?
I am trying to write a simple ACT script based on the user manual.
I write both the .xml and .py files in Notepad++ and save them under the extension folder of Ansys.
My problem is that I can't manage to see the scripted files inside ansys 'manage extension'.
My university has an academic license and I have an access to the Customer Portal.
What should I do?
Just began a fellowship learning Intentive Short-Term Dynamic Therapy (ISDTP). My background is in contextual CBT's (like ACT). I'd love to know both well enough to integrate them. Does anyone have experience in this area?
I obtained my comparison file using blast, however when I load the comparison file on ACT it does not seem to work properly. When I select a feature (cds, inverted region) it seems to select the whole genome (everything goes yellow).. any insights?
As a new professional, I will be working on an ACT Team as the only art therapy provider. Looking for any professionals in the art therapy field who are currently working or have recently worked on this type of team. Thank you in advance for any insight!
I need the ACT extension for ANSYS Workbench 15.0 tool [Its free software available in ANSYS Customer Portal] for selecting and exporting the X,Y,Z coordinates (3D geometry model) for particular node number. This ACT extension for ANSYS Workbench 15.0 tool can be downloaded from ANSYS customer portal by a licensed user.As I am not a licensed user I am not able to download the extension.Can anybody please download it and send it to my mail.I shall be ever grateful to him.My email id is : email@example.com.The link to the customer portal is - https://support.ansys.com/portal/site/AnsysCustomerPortal
After creating geometry in SpaceClaim , to assign material NL hardening, how should I proceed ?
Should it definitely be created in another step ? and how should I use the same system name ?
When I use global systemname
Ansys gives me error that it is not defined , while I have created it in the step 1
I am completing a data request to our State Education Agency for student level data from 2008-2017 and to our state higher education agency . The data at the public school level will contain by year, the annual testing record which includes variables such as sex, race, wealth, special education, annual test results from grade 6-8 (Reading, math, science) and high school English algebra, and biology and the ACT scores and the school last attended. I am merging this data with data from the state university system which will include application to public universities in the state, data will include variable on: application and acceptance, wealth, parent education, freshman GPA, high school GPA, school graduated from plus others.
My research questions focus on the effect of the state public schools mandating ACT testing beginning in 2011-12 and application and acceptance rates, persistence, and freshman grades (GPA) across sex, race, wealth. The data from the university system will have about 50-75 thousand students in it for each year in question.
I am considering using Regression Discontinuity design since I will have at least 4 years of data pre- and post the policy change and enough covariates to deal with any variation on samples. I also thought a Difference in Differences could work, but wanted to hear a few opinions on this before I finalized my request since I need to provide a basic description of the proposed data analysis.
Thanks for your time,
I am trying to genotype mice from Jax (stock #: 021877) using the Sigma Kit (REDExtract-N-Amp™ Tissue PCR Kit) but I dont get bands.
I've tried the protocol suggested by Jax (https://www2.jax.org/protocolsdb/f?p=116:5:0::NO:5:P5_MASTER_PROTOCOL_ID,P5_JRS_CODE:24559,021877) and the one suggested by Sigma (https://www.sigmaaldrich.com/technical-documents/protocols/biology/redextract-n-amp.html). Changed the primers and template concentration already. My ladder works perfectly though. I got band once, but never more
These are my primers:
GCA TGT TTC CTG TTT CGT GA Wild type Forward
GCA TAT TTG GCT TTT ACT CTG G Common
TGG TGG CTG GAC CAA TGT Mutant Forward
Has anyone ever genotyped the same mice strain? Or someone who also had problems with the Sigma PCR kit?
Would appreciate any help!
I am a firm believer in the potential benefits of ACT for a range of difficulties.
Do people have information about ACT for sleep?
Does anyone have clinical experience of using ACT-related interventions and a sense of how successful the interventions were?
Hi, I came across your iGuide challenge paper. I am a teacher in the ACT at a school with high number of indigenous students. As it happens I am aware of B. Bernstein. I am very influenced by Paulo Freire too. Pedagogies, school wellbeing and disadvantage is a key concern as well.
I am looking for a relationship/difference between two sets of scores (state test vs. ACT). The problem is that one is on a 450-point scale and one is on a 36-point scale. I've tried the t-test, but I keep getting a straight-up "O" on it.
Can someone tell me a better test to use or a way to get these scores to be "compatible" for the t-test?
I conducted harmonic analysis using ANSYS workbench with memes and piezoelectric ACT extension trying to get an understanding of the behavior of the piezo material as the displacement varies harmonically. My question is about the term voltage frequency plot term mentioned in the results tab and what does it mean, and is the resulting plot represents the frequency spectrum of the output voltage that corresponds to the frequency spectrum of the input harmonic force and the resulting frequency spectrum of the displacement?
need help please to clarify things and any help regarding the piezo material simulation is also welcomed.
We know the glial cells surround neurons and provide support for and insulation between them.Glial cells are the most abundant cell types in the central nervous system.But this definitions are underestimating them.
For over a century, it was believed that the glial did not play any role in neurotransmission. However 21st century neuroscience has recognized that glial cells do have some effects on certain physiological processes like breathing, and in assisting the neurons to form synaptic connections between each other.
As I understand, glial function is self acting.A micro system to decide individually and act individually.
It recalls me to concept of "Automata". The word automata (the plural of automaton) comes from the Greek word αὐτόματα, which means "self-acting".
The main question is if we could model the function of glial with automata?
If it's suitable even to ask this question or not?
please share your thoughts with me.
I've been trying to access safety factor result from ANSYS ACT through command lines on ACT Console. But, when i get the resultNames, no one is the safety factor result (rather than deformation, stress, etc, that appears). The image show my situation.
Please, help me. Thanks!
I am Solving a pressure vessel problem with internal pressure and the Covers bolted on to the housing. Currently all the contacts are defined as bonded (MPC). the assembly is placed on a plate which is in turn fixed, and bonded contact is defined between the vessel legs and the plate. The pretension in the bolts is 50000N given in 4 steps ( 1000N,15000, 30000, 50000). also each step is divided into minimum 50 substeps. But am getting the above error when the solver reaches the second step (15000). The UX direction in the error is along the axis of the bolt, i am unable to track the offending body as i was not able to track the pretension node through ansys ACT extension.
We are looking at GAF and we know that HoNOS has been used for ACT before.
Looking to measure occupational functioning.
I am conducting a research focusing on the impact of maternal mental health in the childhood asthma control and I need to know which is the best test to be done in a Primary Care.
Some researchers said that Grain boundaries act as obstacles to slip dislocations causing dislocations to pile up on their slip planes behind the boundaries but others said that grain boundaries can become efficient sinks for dislocations. That is a contradiction for me. Can anyone help me to clarify this?
As a student of this profession, it is common to find in our work the appearance of ethical dilemmas, but I still do not understand how I could face them, besides being interested in knowing some experiences of people in that profession.
Generally, data compression is the act of removing redundancy (a lack of distinction, also know as repetition or order), and as de Bruijn sequences are maximally disordered, it must be the task of data compressors to approximate de Bruijn sequences in their output. With sufficient understanding of such translation processes, we might the decode existing de Bruijn sequences, and observe the hidden order of their message, as interpreted by decompression software. The same goes for cryptographic processes.
A waveform may get spikes due to lightning and other sources of surges. It is necessary to remove the spike from the waveform and compensate with an auxiliary supply.But for this the relay has to operate and reclose within few milliseconds
I am wondering why some protein inhibitors increase the levels of target protein and still known as their inhibitors? For example MCL1 inhibitor S63845 increase the levels of MCL1 in tumor cells (Kotschy et al., Nature 538, 477–482). I understands that these inhibitors mostly act to inhibit protein-protein interactions. Like, in this case S63845 inhibits interaction of MCL1 with BAK and BAX, thereby facilitates the availability of BAK and BAX for downstream apoptotic pathway. But, It always confuses me why it is known as a inhibitor of MCL1?
I am working on characterizing the function of a gene under stress. The T-DNA lines were obtained from SALK. The miRNA was prepared in lab and it shows very insignificant expression of my gene. Further, the 35S:over-expression lines were also generated in own lab with expression many fold to be qualified as a successful OX-lines. Currently, I am using the single T-DNA line (insertion at intron) and 3 each miRNA and Overexpression lines. I see a stress phenotype in all of them, but not in WT. Why is this weird phenotype? I understand the fact that sometimes due of presence of promoter enhancing sequences in the T-DNA, the T-DNA lines act as ox-line. But, the qRT data shows very low gene expression in my T-DNA mutant, removing the ambiguity of over-expression. Please provide your useful insight.
Further, the miRNA can be distinguished from my OX-lines by different in root length on 1/2 MS media under normal conditions. miRNA is significantly longer than the OX-expression, WT and the T-DNA line. WT and T-DNA almost same root length. The Over-expression lines shows the shortest root lengths.
Anybody knows that when the adjuvant chemotherapy (ACT) of colon cancer was recommended for the first time in the guidelines?
The first evidence of the survival benefit of 5FU-based ACT over surgery alone in stage II-III colon cancer patients was reported from NSABP C-01 trial in 1988, which was afterward confirmed by later pooled analyses. Following these pioneering studies, 5FU deemed to be the standard control arm in newer CRTs which were consequently unable to investigate the effectiveness of the innovative surgery alone treatments (e.g. complete mesocolic excision) of colon cancer. Surprisingly, The disease-free and overall survival benefit of ACT reported in NSABP C-01 trial disappeared after ten years in an updated analysis, making a glass ceiling for the real effectiveness of ACT in clinical practice. I am working on this story and would like to know how the ACT came to the guidelines as a standard treatment of colon cancer.
we want to to evaluated effect of acceptance commitment therapy on tolerating pain in patients with multiple sclerosis, so is there any protocol for this therapy in these patients?
- I would like to extract the S-parameter using ADS. However, i have been having some difficulties. Firstly, i cannot calculate the capacitor at the input and output of the circuit. (Both capacitor must act like a DC block to the 50 ohms termination). I have considered the Self Resonating Frequency (SRF). However, I get varying answers.
- What is the resolving this problem?
- Is the Self resonating frequency the same as the operating frequency?.
- I also need to calculate the DC feed element. Do i still have to use the SRF? Thanks for your assistance and suggestions.
We are studying Malaria drugs resistance, and we found that the % of early treatment failure in P. falciparum infected patients treated with ACT higher among children below 5 years.
Is this normal or explanable ?
I am curious to look at a trend in ACT data over the past 5 years or so. Is there a database that exist out there somewhere?
I constructed a third-order reflective model of psychological empowerment (see model in attachment), which is composed by:
- 12 first-order latent variables: PC, ACT, CIE, OCE, PTR, PF, SI, CC, CP, OI, SN, and SB
- 3 second-order latent variables: CE (reflected in PTR, PF, and SI), RE (reflected in CC, CP, OI, SN, and SB), and BE (reflected in ACT, CIE, and OCE).
To establish the measurement model of higher-order variables, all the indicators from the lower-order variables were assigned to the higher-order variables in the form of a repeated indicators approach.
Then, CTA-PLS was used to investigate the directionality for indicators associated with the psychological empowerment construct (see CTA-PLS results in attachment)
1) Should I use significance test at p = 0.1 or 0.05 level?
2) Since I'm testing for multiple model-implied vanishing at the same time, should I assess the significance of the tetrads based on CI Low adj. and CI Up Adj. values?
3) Should I analyze both first and second-order LV results? Should I report all the results in the paper (it's a very long table...)
4) Taking into account the results, 3 first-order LV (SI, SB and SN) and 1 second-order LV (RE) are formative ([CI Low Adj., CI Up Adj.] don't include 0). Should I conclude that psychological empowerment model is better measured formatively?
Your help will be sincerely appreciated.
Is it possible to measure the reduction of Cytochrome C by Complex III, by measuring OD at 550 nm in absence of ubiquinol? If yes, the what will act as the electron donor for Complex III?
My qPCR results show that my PBMCs express pluripotency markers such as SOX2, NANOG, among others as much as my iPSCs. I found a couple of papers that discuss that a subset of PBMCs act as pluripotent stem cells.
Has anyone encountered this before?
Thanks in advance!
When I was reading about quorum sensing mechanism, it seems to be that they are bacteriostatic. But, their are reports which are saying that QS agents can act as an antibacterial.
Can anybody suggest me the answer?
The abstract says that training in use of ACT did not improve the right use. Right use dependent on general experience over time; nevertheless the conclusion ask for more training in use of ACT. I do not understand it .
How can i examine kinetics of ROS production?
Objective: To what extent or what amount ROS act as signalling compound and would not cause considerable oxidation and after that specific level, ROS starts oxidation.
Suggestion regarding protocols of finding kinetics of ROS
Hi, has anyone experience small litter size for mice. Basically I have a set of litter which are smaller than the usual size (observed at 3 wk age) and also their tails are much shorter than normal. The male is CRE+; SEPT9:fl/ +; Act tom: mut/ mut. This is bred with female of similar genotype that is CRE+; SEPT9: fl/ +; Act tom: mut/ mut. The litters do look perfectly healthy and behave normal as other litters would at the age (3 wks). Has anyone faced small mice litter during breeding? If so, please could you share your experience as to why this happens and if they have any changes when they grow further. Thanks in advance... Susmita
Prior to joining this site, I have found a great deal of literature on suicide prevention work with adolescents in both individual and group formats. I am familiar with ACT and DBT and I'm curious about research specifically on suicide prevention for adults. The CBT-SP model (individual and supplementary group) seems modifiable to suit adults, so I wonder if there is some reason I'm not getting that keeps us from implementing CBT-SP on a wider scale. Many troubled adults feel very "held" by structure. Regardless, the issues that must be dealt with are likely to be harrowing, and group support and experiential insight could be exponentially effective for post-crisis individuals. Aside from cohesion, mindfulness and grounding, what would you do with such a group? How can you work with the group to take hope out of the dissociative realm and make positive or rational thinking feel more real?
After how many minutes, according to the protocol of your department, it is advisory to sample blood for ACT after heparin dose administration before the commencement of CPB?
My work aims to assess the the concept of a resurgent Keynesianism following the GFC with reference to the American Reinvestment Act and other suitable case study examples. The role of new theoretical approaches to local and regional development will also be discussed as part of this critical analysis.